vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Ares Commercial Real Estate Corp is the larger business by last-quarter revenue ($13.2M vs $7.0M, roughly 1.9× Relay Therapeutics, Inc.).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
ACRE vs RLAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $7.0M |
| Net Profit | $-3.9M | — |
| Gross Margin | — | — |
| Operating Margin | -29.2% | — |
| Net Margin | -29.2% | — |
| Revenue YoY | -24.5% | — |
| Net Profit YoY | 63.8% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $7.0M | ||
| Q3 25 | $14.1M | $0 | ||
| Q2 25 | $12.6M | — | ||
| Q1 25 | $14.9M | $7.7M | ||
| Q4 24 | $17.5M | $0 | ||
| Q3 24 | $16.7M | $0 | ||
| Q2 24 | $16.8M | $0 | ||
| Q1 24 | $18.7M | $10.0M |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $4.7M | $-74.1M | ||
| Q2 25 | $-11.0M | — | ||
| Q1 25 | $9.3M | $-77.1M | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-5.9M | $-88.1M | ||
| Q2 24 | $-6.1M | $-92.2M | ||
| Q1 24 | $-12.3M | $-81.4M |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | — | ||
| Q1 25 | 64.4% | -1105.2% | ||
| Q4 24 | -61.0% | — | ||
| Q3 24 | -35.3% | — | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | -903.0% |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | — | ||
| Q1 25 | 62.5% | -1003.6% | ||
| Q4 24 | -60.9% | — | ||
| Q3 24 | -35.3% | — | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | -813.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.43 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.46 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.63 | ||
| Q2 24 | — | $-0.69 | ||
| Q1 24 | — | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $84.0M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $567.1M |
| Total Assets | $1.6B | $621.3M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $84.0M | ||
| Q3 25 | $84.9M | $91.6M | ||
| Q2 25 | $90.0M | — | ||
| Q1 25 | $125.5M | $93.5M | ||
| Q4 24 | $63.8M | $124.3M | ||
| Q3 24 | $68.9M | $152.4M | ||
| Q2 24 | $70.6M | $134.1M | ||
| Q1 24 | $99.5M | $152.9M |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | $567.1M | ||
| Q3 25 | $521.0M | $607.7M | ||
| Q2 25 | $523.7M | — | ||
| Q1 25 | $542.1M | $721.1M | ||
| Q4 24 | $540.1M | $777.8M | ||
| Q3 24 | $563.8M | $838.9M | ||
| Q2 24 | $582.3M | $681.7M | ||
| Q1 24 | $601.1M | $745.8M |
| Q4 25 | $1.6B | $621.3M | ||
| Q3 25 | $1.4B | $670.0M | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.5B | $799.4M | ||
| Q4 24 | $1.8B | $871.3M | ||
| Q3 24 | $1.9B | $930.1M | ||
| Q2 24 | $2.1B | $772.5M | ||
| Q1 24 | $2.1B | $841.4M |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-235.5M |
| Free Cash FlowOCF − Capex | — | $-235.9M |
| FCF MarginFCF / Revenue | — | -3370.0% |
| Capex IntensityCapex / Revenue | — | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $-235.5M | ||
| Q3 25 | $3.8M | $-62.1M | ||
| Q2 25 | $4.9M | — | ||
| Q1 25 | $8.0M | $-73.2M | ||
| Q4 24 | $35.5M | $-249.1M | ||
| Q3 24 | $8.4M | $-75.1M | ||
| Q2 24 | $8.7M | $-65.8M | ||
| Q1 24 | $11.4M | $-50.3M |
| Q4 25 | — | $-235.9M | ||
| Q3 25 | — | $-62.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-73.6M | ||
| Q4 24 | — | $-251.1M | ||
| Q3 24 | — | $-75.3M | ||
| Q2 24 | — | $-65.8M | ||
| Q1 24 | — | $-52.1M |
| Q4 25 | — | -3370.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -958.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -520.7% |
| Q4 25 | — | 5.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 17.8% |
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
